Melbourne researchers have uncovered genes responsible for the way the body fights infection at the point of ‘invasion’ – whether it’s the skin, liver, lungs or the gut.
Research led by Dr Axel Kallies and Dr Klaas van Gisbergen at the Walter and Eliza Hall Institute of Medical Research, and Dr Laura Mackay from the University of Melbourne at the Peter Doherty Institute for Infection and Immunity has identified the genes Hobit and Blimp1 and found that they control a universal molecular program responsible for placing immune cells at the ‘front lines’ of the body to fight infection and cancer.
The presence of these organ-residing cells, which differ strikingly from their counterparts circulating in the blood stream, is key to local protection against viruses and bacteria.
Walter and Eliza Hall Institute’s Dr Kallies said the human body was fighting disease-causing pathogens every minute of its life. Dr Kallies said identifying how immune cells remain in the part of the body where they are needed most was critical to developing better ways to protect us from infections such as malaria or HIV.
“Discovering these ‘local heroes’ and knowing how the localised immune response is established allows us to find ways to ensure the required cells are positioned where they are needed most,” Dr Kallies said.
“This research will help us understand how immune cells adapt, survive and respond within the organs they protect. This is critical to rid the body of pathogens even before they are established and may also have implications for understanding how the spread of cancer could be prevented.”
The Doherty Institute’s Dr Laura Mackay, who is also an associate investigator with the Australian Research Council Centre of Excellence in Advanced Molecular Imaging, said the factors that control the ‘tissue-residency’ of immune cells – their ability to locally reside in different organs of the body – was previously unknown.
“These results have major implications for developing strategies to induce immune cells in tissues that protect against infectious diseases,” Dr Mackay said.
“It’s a crucial discovery for future vaccine strategies – Hobit and Blimp1 would be key to placing immune cells in the tissues, which we know are really important for protection.”
The Latest on: Localised immune response
via Google News
The Latest on: Localised immune response
- Portable microwave tech used in treating skin lesions on November 9, 2018 at 6:32 am
efficient treatment for AK and other lesions that would benefit from a localised immune response therapy. "The funding from Innovate UK has been key in allowing this project to happen and helps the co... […]
- The truth about rabies – a much-needed wakeup call on September 27, 2018 at 6:54 pm
But even if the bite is localised to hands or feet ... the body’s immune function and prevent the rabies vaccine from helping to mount an adequate immune response to the virus. Because of this, it is ... […]
- Tiny Tunnels Previously Unknown to Scientists Found Between the Skull and Brain on August 30, 2018 at 12:28 am
The researchers say a molecule known as SDF-1 is the likely agent in this collaboration, setting off a localised immune response. This is a very cool finding on its own, but it gets even better. Armed ... […]
- Apitope Announces Positive Results with Novel Treatment for Graves' Disease on April 16, 2018 at 12:35 am
It is characterized by an immune response against the extracellular domain of the thyroid ... Symptoms of Graves' disease can include an enlargement of the thyroid gland, swelling of the neck, localis... […]
- Nanotechnology hits the spot in arthritis treatment on October 7, 2017 at 10:16 pm
Her strategies promise to target pathways associated with inflammation, while leaving other vital immune responses unaffected ... that intravenously injected peptide-siRNA nanocomplexes localised to t... […]
- PCI Biotech: Initial clinical results from Phase I indicate that vaccination with fimaVACC enhances cellular immune responses on September 11, 2017 at 11:10 pm
Oslo (Norway), 12 September 2017 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that ... […]
- PCI Biotech: Initial clinical results from Phase I indicate that vaccination with fimaVACC enhances cellular immune responses on September 11, 2017 at 5:00 pm
Oslo (Norway), 12 September 2017 - PCI Biotech (PCIB.OL), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that t... […]
- Key first steps to inflammatory arthritis identified on January 23, 2017 at 12:39 am
That reaction results when a localised accumulation of immune complexes - antibodies bound to their antigens - is deposited in tissue and sets off an inflammatory response involving the infiltration a... […]
- Researchers uncover 'local heroes' of immune system on April 22, 2016 at 6:32 am
"Discovering these 'local heroes' and knowing how the localised immune response is established allows us to find ways to ensure the required cells are positioned where they are needed most," Dr Kallie... […]
- Argos begins pilot clinical trial of AGS-003 as neoadjuvant immunotherapy for localized renal cell carcinoma on August 12, 2015 at 3:11 am
and we look forward to advancing research to determine whether this therapy can help the body build an effective immune response to kill tumour cells in patients with localised disease. The goal is to ... […]
via Bing News